EA201071218A1 - Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью - Google Patents

Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью

Info

Publication number
EA201071218A1
EA201071218A1 EA201071218A EA201071218A EA201071218A1 EA 201071218 A1 EA201071218 A1 EA 201071218A1 EA 201071218 A EA201071218 A EA 201071218A EA 201071218 A EA201071218 A EA 201071218A EA 201071218 A1 EA201071218 A1 EA 201071218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active pharmaceutical
improved compositions
permeability
pharmaceutical components
bad permeability
Prior art date
Application number
EA201071218A
Other languages
English (en)
Other versions
EA032766B1 (ru
Inventor
Ян П. Мешвитцер
Алдо Кет
Хайке Динтерхайдорн
Original Assignee
Эбботт Продактс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Продактс Гмбх filed Critical Эбботт Продактс Гмбх
Publication of EA201071218A1 publication Critical patent/EA201071218A1/ru
Publication of EA032766B1 publication Critical patent/EA032766B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к пероральной фармацевтической лекарственной форме, которая содержит активный фармацевтический компонент с плохой проницаемостью и по меньшей мере одно вещество, улучшающее проницаемость, где вещество, улучшающее проницаемость, термостабильно встроено в водорастворимую матрицу из водорастворимого носителя, и к термостабильным составам, которые можно использовать для улучшения биодоступности.
EA201071218A 2008-04-22 2009-04-21 Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью EA032766B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103657 2008-04-22
PCT/EP2009/054720 WO2009130204A2 (en) 2008-04-22 2009-04-21 Improved formulations for poorly permeable active pharmaceutical ingredients

Publications (2)

Publication Number Publication Date
EA201071218A1 true EA201071218A1 (ru) 2011-06-30
EA032766B1 EA032766B1 (ru) 2019-07-31

Family

ID=39816874

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071218A EA032766B1 (ru) 2008-04-22 2009-04-21 Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью

Country Status (18)

Country Link
US (1) US20090263479A1 (ru)
EP (1) EP2268270A2 (ru)
JP (1) JP5726067B2 (ru)
KR (1) KR20110005883A (ru)
CN (1) CN102119025B (ru)
AR (1) AR071375A1 (ru)
AU (1) AU2009240050A1 (ru)
BR (1) BRPI0910758A2 (ru)
CA (1) CA2720658C (ru)
CO (1) CO6300932A2 (ru)
DO (1) DOP2010000318A (ru)
EA (1) EA032766B1 (ru)
EC (1) ECSP10010514A (ru)
IL (1) IL208370A0 (ru)
MX (1) MX2010011564A (ru)
NZ (1) NZ588369A (ru)
TW (1) TW200948399A (ru)
WO (1) WO2009130204A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
EP2900219B1 (en) 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
EP2911651B1 (en) 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US20150366823A1 (en) * 2013-02-06 2015-12-24 Hermes Arzneimittel Gmbh Pharmaceutical compositions incorporating low-dose drugs
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
EP3157506B1 (en) 2014-06-20 2020-08-26 Hermes Arzneimittel GmbH Taste-masked oral pharmaceutical composition
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
US20230172866A1 (en) * 2020-03-18 2023-06-08 Sichuan Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
CN112704649A (zh) * 2020-12-30 2021-04-27 广东臻香荟生物科技有限公司 一种具备抑菌性能的香薰液
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN114601800B (zh) * 2021-09-28 2023-07-28 天津瑞普生物技术股份有限公司 一种甲磷丙泊酚钠无菌粉针剂及其制备方法
US20230277464A1 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3477864A (en) * 1965-05-07 1969-11-11 Sumitomo Chemical Co Process for coating pharmaceutical preparations with a hydroxy propyl methyl cellulose-sealing agent moisture-preventing film
US3692543A (en) * 1971-01-28 1972-09-19 Wellman Lord Inc Food products
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
JPH085086B2 (ja) * 1992-07-14 1996-01-24 メリート株式会社 金型装置
DE19709532A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
ES2627842T3 (es) * 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Formas de dosificación de liberación controlada
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US7262184B2 (en) * 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US20070065513A1 (en) * 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
US20060240108A1 (en) * 2005-04-26 2006-10-26 Bernard Bobby L Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
EP1983966B1 (en) * 2006-02-09 2013-06-26 Merck Sharp & Dohme Corp. Polymer formulations of cetp inhibitors
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Also Published As

Publication number Publication date
BRPI0910758A2 (pt) 2018-03-20
JP5726067B2 (ja) 2015-05-27
CO6300932A2 (es) 2011-07-21
MX2010011564A (es) 2011-03-02
DOP2010000318A (es) 2011-01-15
ECSP10010514A (es) 2010-11-30
CA2720658C (en) 2016-07-12
TW200948399A (en) 2009-12-01
EA032766B1 (ru) 2019-07-31
JP2011518208A (ja) 2011-06-23
CA2720658A1 (en) 2009-10-29
WO2009130204A2 (en) 2009-10-29
WO2009130204A3 (en) 2010-08-05
AU2009240050A1 (en) 2009-10-29
CN102119025B (zh) 2014-09-03
US20090263479A1 (en) 2009-10-22
EP2268270A2 (en) 2011-01-05
CN102119025A (zh) 2011-07-06
IL208370A0 (en) 2010-12-30
AR071375A1 (es) 2010-06-16
NZ588369A (en) 2012-06-29
KR20110005883A (ko) 2011-01-19

Similar Documents

Publication Publication Date Title
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
TR200806298A2 (tr) Farmasötik formülasyon
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
MX2010009851A (es) Oblea gingival.
UA107582C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
EA201170512A1 (ru) Композиция для перорального введения
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201071309A1 (ru) Твердая фармацевтическая композиция
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
EA201390911A1 (ru) Фармацевтическая композиция, содержащая растительное действующее вещество
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
EA201290250A1 (ru) Композиция, содержащая фезотеродин и балластные вещества
TR201007653A2 (tr) Eplerenon içeren farmasötik kompozisyon
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
ECSP078024A (es) Inhibidores de la adenilato ciclasa soluble
EA200701227A1 (ru) Замещённые индолы, содержащие их композиции, способ получения и применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM